Melanotan II

Clinical Summary

Melanotan II (MT-2) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), first synthesized at the University of Arizona in the late 1980s by Hruby and Hadley. It is a non-selective melanocortin receptor agonist that binds MC1R, MC3R, MC4R, and MC5R with high affinity (does NOT bind MC2R/ACTH receptor). Originally developed to induce protective tanning without UV exposure, it was later found to cause penile erections as an incidental finding during Phase I trials.

Who uses it (in practice): Individuals seeking cosmetic tanning without UV exposure, and off-label for sexual dysfunction. Purchased almost exclusively from unregulated gray-market sources online.

The honest reality: Only 4 small clinical trials in humans have ever been published (total N < 70, all from the University of Arizona group, 1996-2000). No Phase III trials. No RCTs beyond one small crossover (N=10). Pharmaceutical development was abandoned circa 2003 due to the non-selective receptor profile causing too many off-target effects (nausea, cardiovascular changes, priapism). The derivative bremelanotide (PT-141/Vyleesi), which emerged from MT-2 research, received FDA approval in 2019 for hypoactive sexual desire disorder in women — but MT-2 itself was never submitted for approval. MT-2 was explicitly EXCLUDED from the Feb 2026 Kennedy HHS peptide reclassification — it remains FDA Category 2 (not compoundable), unlike BPC-157 which was liberalized.

Social media amplification (2024-2026): The "Barbie drug" TikTok trend drove MT-2 nasal spray viral among young UK women (18-25). BBC/Imperial College London analysis of tested products found 200+ unidentified compounds. TikTok banned MT-2 hashtags but products persist under generic tags.

Why development stalled: MT-2's non-selective binding to MC3R/MC4R/MC5R alongside MC1R produces a side-effect profile (nausea, BP changes, sexual effects, appetite suppression) that made it unsuitable for FDA approval. The pharmaceutical industry pivoted to selective derivatives: afamelanotide (MC1R-selective, approved as Scenesse for EPP) and bremelanotide (MC4R-preferring, approved as Vyleesi for HSDD).

2026 development: After 20+ years of dormancy, NCT07437560 (Hudson Biotech) is recruiting for a Phase 2 RCT of MT-II + NB-UVB phototherapy for stable nonsegmental vitiligo (N=60, randomized, placebo-controlled). This is the first registered Phase 2 trial of MT-II itself — not a derivative — indicating renewed commercial interest in the compound as a distinct therapeutic entity. Completion expected 2028.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal data only OR very limited human | 1/5 No evidence / theoretical / debunked

Human Study Details

Study 1 — Phase I Pilot, Pigmentation (PMID: 8637402) Dorr RT, Lines R, Levine N et al. (1996). Life Sci. N=10 healthy volunteers. Double-blind, dose-escalation. SubQ 0.01-0.025 mg/kg daily x 5 days. Significant melanin increase measured by spectrophotometry at 0.025 mg/kg. Dose-limiting toxicity: nausea, facial flushing, fatigue. This is the foundational human trial for MT-2.

Study 2 — Psychogenic ED, Double-blind Crossover (PMID: 9679884) Wessells H, Fuciarelli K, Hansen J et al. (1998). J Urol. N=10 men with psychogenic ED. Double-blind, placebo-controlled crossover. Single SubQ dose of 0.025 mg/kg. 8/10 showed erection response (RigiScan) vs 1/10 on placebo (p<0.05). Best-designed MT-2 human study. Small N but proper RCT methodology.

Study 3 — Organic ED (PMID: 11018622) Wessells H, Gralnek D, Dorr R et al. (2000). Urology. N=19 men with organic ED. SubQ 0.025 mg/kg. More modest response than psychogenic ED — erections occurred but insufficient for intercourse in many. Nausea prominent.

Study 4 — Sexual Motivation (PMID: 11035391) Wessells H, Levine N, Hadley ME et al. (2000). Int J Impot Res. N=20 healthy men. Open-label, multiple SubQ doses over weeks. Increased sexual desire, spontaneous erections, and penile tumescence. Combined with skin darkening. Open-label design limits conclusions.

The Bremelanotide (PT-141) Lineage

MT-2 research led to bremelanotide (PT-141), a metabolite of MT-2 that preferentially activates MC4R over MC1R (less tanning, targeted sexual effects). Bremelanotide received FDA approval as Vyleesi in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women based on the RECONNECT Phase 3 trials (PMID: 31599840). This validates the MC4R mechanism for sexual function but does NOT validate MT-2 itself.

Key bremelanotide PMIDs: 35147466 (safety profile), 31599840 (Phase 3 RECONNECT), 31277966 (Phase 2b dose-ranging), 27977473 (ambulatory BP monitoring), 27181790 (female sexual dysfunction dose-finding).

Prescribing

Dosing

CRITICAL CAVEAT: No dose-finding study has been completed. All "protocols" below are derived from (a) the Phase I study and (b) community practice with zero clinical validation.

Dose discrepancy: The Phase I trial used ~1.75 mg/dose (0.025 mg/kg), which is 3-7x higher than the community loading dose of 250-500 mcg. Community protocols likely evolved toward lower doses because the Phase I dose caused severe nausea in most subjects.

Formulations

Route ranking: SubQ 4/5 > Intranasal 2/5 (unreliable absorption) > All others 1/5 Oral administration is ineffective — peptide is degraded by gastric acid. No oral bioavailability data exists.

Safety

Adverse Effects — Phase I Data (PMID: 8637402)

Serious Adverse Events — Case Reports

FAERS Signal Table (from BioMCP)

Reading FAERS data: Only 7 total FAERS reports exist for melanotan (all formulations), representing ~2-3 unique patients. Only 1 unique patient has MT-2 as the suspect drug (renal infarct). This is consistent with the FAERS noise pattern for unregulated peptides — very low report volume, dominated by duplicates and concomitant-drug artifacts. The vast majority of MT-2 adverse events are reported through case reports in the medical literature, not through FAERS. MT-2 is not in FDA's approved drug database, so FAERS capture is inherently poor.

Melanoma / Nevi Risk — Critical Concern

MT-2 stimulates melanocyte proliferation and melanin production via MC1R. This raises a theoretical and clinically observed concern:

1. Eruptive nevi are well-documented — multiple case reports of new or changed moles during MT-2 use (PMIDs: 23914578, 19380666, 23052015). A 2019 review confirmed melanotan as a recognized trigger for eruptive melanocytic nevi (PMID: 31119650).
2. Melanoma case reports exist — cutaneous melanoma (PMID: 24355990) and oral mucosal melanoma (PMID: 40210573) in MT-2 users. Causality is NOT proven (melanoma has long latency and multiple risk factors), but biological plausibility is strong.
3. No long-term epidemiological data exists — we cannot quantify the actual melanoma risk. The absence of evidence is not evidence of absence.
4. Paradox: One preclinical study (PMID: 31968661) found topical MT-II suppressed melanoma growth via PTEN upregulation and COX-2 inhibition. This does NOT resolve the safety concern — melanocyte stimulation and tumor suppression may operate through different pathways.
5. TGA cited 2 melanoma cases in 89 adverse event reports (2022-2025) as part of their justification for reclassifying MT-2 to Schedule 9 in February 2026.
6. BJD observational cohort (2026): Among 89 respondents who used MT-2 continuously for >2 years, 12 were subsequently diagnosed with melanoma. Authors explicitly stated this does NOT establish causation — cohort was Fitzpatrick I-II (already elevated baseline risk 2-3% lifetime) and likely concurrent UV-seekers.
7. Bohm et al. (2025, PMID: 39082868): JEADV review from Munster/Gustave Roussy/Harvard/Cambridge. MC1R activation induces pigmentation + DNA repair + controls aberrant cell growth — may actually REDUCE melanoma risk. But does NOT prevent melanoma. Important: this review focuses on selective MC1R agonists (afamelanotide, setmelanotide); MT-2's non-selective profile makes extrapolation uncertain.
8. Oral mucosal melanoma (PMID: 40210573): 22-year-old female, nasal spray user. Oral mucosa is NOT UV-exposed — suggests MC1R-driven melanocyte stimulation independent of UV. The most concerning single case report in the literature.
9. Confounding factor: Many MT-2 users also use UV tanning beds (a known melanoma risk factor). Disentangling MT-2 risk from UV risk is impossible without controlled studies.

Bottom line on melanoma risk: Biologically plausible, case-report supported, but unquantified. Anyone with a personal or family history of melanoma, atypical mole syndrome, or fair skin with many moles should consider MT-2 absolutely contraindicated.

Interactions

Contraindications

Absolute:

• History of melanoma or atypical mole syndrome / dysplastic nevi
• Known hypersensitivity to MT-2 or excipients
• Pregnancy and lactation — zero safety data; melanocortin receptors expressed in placenta
• Active priapism or conditions predisposing to priapism (sickle cell disease, etc.)

Relative (use with extreme caution):

• Fair skin with many moles — heightened melanoma risk
• Family history of melanoma
• Cardiovascular disease / uncontrolled hypertension — transient BP increases documented
• Renal impairment — renal infarction case report (PMID: 31953620)
• Hepatic impairment — presumed hepatic metabolism
• Concurrent PDE5 inhibitor use
• Autoimmune conditions — melanocortin-immune axis interactions unknown
• Pediatric (<18) — zero data

Monitoring

Stop immediately if: new mole or changing mole, priapism (erection >4 hours), chest pain or severe headache, BP >160/100, severe nausea/vomiting not improving, rhabdomyolysis symptoms (dark urine, severe muscle pain), any anaphylactic signs.

Synergies & Stacking

No evidence-based synergies exist. MT-2 is typically used alone. Combining with other peptides (e.g., BPC-157, TB 500) is underground practice without evidence. Combining with PDE5 inhibitors is explicitly dangerous (priapism risk).

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance. A peer-reviewed qualitative study of MT-2 forum behavior exists (Gilhooley et al. 2021, PMID: 34464955).

Dominant Sentiment

Strongly positive for tanning efficacy, mixed overall across ~5,000+ unique posters (Reddit r/Peptides, r/Melanotan2, r/PEDs, bodybuilding forums, UK/Australian tanning communities, Looksmax.org). The peer-reviewed Gilhooley study (N=205 forum participants, 623 discussion entries) confirmed motivations: holiday preparation, fitness competitions, year-round aesthetics. Turnock & Hearne (2024) netnography of 493 UK forum threads (~15,000 posts) documented folk pharmacology and harm reduction practices. McKenzie et al. (Mayo Clinic, 2024-2026) surveyed user beliefs, attitudes, and experiences via JAAD/BJD abstracts.

Emerging community (2024-2026): Looksmax.org — male aesthetics forum with detailed MT-2 "mega guides." Users seek skin darkening as facial aesthetics enhancement ("phenotype optimization"). Demographics skew younger (18-24 male) than Reddit r/Peptides. N-size: hundreds of active threads. Red flag: subculture-specific dehumanizing language for pale skin.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None detected. Commercial model is vendor-direct (TruTan, PrestigeTan, PureMT2 in UK) with blog/forum-driven marketing. Obvious conflict of interest: vendors produce the "education" content.
• Influencer concentration: TikTok "Barbie drug" trend driven by beauty influencers (18-25 yo women). Derek/MPMD provides pharmacologically literate coverage. Ben Greenfield, Jay Campbell mentioned.
• Astroturfing signals: UK vendor forums (TruTan, PrestigeTan) are vendor-controlled — all content is promotional. Reddit r/Peptides self-polices but vendor seeding occurs.
• Commercial bias: Near-zero negative content on social media (confirmed by BJD systematic review of social media content). The information environment is overwhelmingly promotional.
• Product quality crisis: BBC/Imperial College London analysis found 200+ unidentified compounds in tested MT-2 products (vs ~10 in licensed medicines). Forensic analysis (PMID: 39302005) found seized MT-2 at 30% purity. Users recommend Janoshik/Finnrick third-party testing.
• "Barbie drug" trivializes risk: The nickname normalizes injecting an abandoned pharmaceutical. TikTok banned MT-2 hashtags but products persist under generic tags. Nasal spray searches up 300%+ since spring 2024 (UK CTSI 2025). New vendor sites (TurboTanStar, SoDamnTanned) appearing alongside established PureMT2/TruTan.
• Tanorexia / BDD overlap: Tanning addiction ("tanorexia") intersects with MT-2 use. Female sex, BDD, and OCD screening positivity are significantly associated with tanning dependence. MT-2 enables compulsive tanning behavior by accelerating results. No MT-2-specific addiction studies exist, but no classical withdrawal syndrome reported — dependency is behavioral (loss of tan), not pharmacological.
• East Asian community absence: Zero MT-2 discussion found in Japanese, Korean, or Chinese biohacker communities. MT-2 use is overwhelmingly Western (UK, Australia, US, Scandinavia) — culturally aligned with tanning preference vs East Asian skin-lightening preference.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: (1) tanning efficacy, (2) nausea as universal side effect, (3) pro-erectile effects, (4) appetite suppression, (5) new mole formation. Community experience diverges from clinical data on: (1) optimal dosing — community uses 3-7x lower doses than Phase I, with no data on whether these doses are equally effective or safer for melanoma risk; (2) nasal spray efficacy — no PK data exists for intranasal delivery despite widespread UK use; (3) long-term safety — community "5+ year veterans" report no problems, but melanoma latency is 10-20 years and no surveillance exists; (4) the Longecity case of persistent libido loss suggests a possible MC4R desensitization mechanism not captured in short-term trials. The peer-reviewed Gilhooley study (2021) confirmed that users develop an "emergent folk pharmacology" on forums that becomes community standard without clinical validation.

Deep Dive: Mechanisms & Research

Receptor Binding Profile

Key Structural Modifications (vs natural alpha-MSH)

• Methionine-4 → Norleucine (Nle): Improves metabolic stability, prevents oxidation
• Phenylalanine-7 → D-Phenylalanine (D-Phe): Increases receptor binding affinity and enzymatic resistance
• Cyclization via lactam bridge (Asp-5 to Lys-10): Confers resistance to proteolytic degradation, enhances potency ~1000-fold over alpha-MSH

Downstream Pathways

MC1R activation (pigmentation): Binding stimulates adenylyl cyclase → cAMP → PKA → CREB phosphorylation → MITF and tyrosinase upregulation. Converts tyrosine to eumelanin (brown/black) and pheomelanin (red/yellow). Net: darker pigmentation independent of UV.

MC4R activation (sexual function): Central MC4R in paraventricular nucleus and medial preoptic area → oxytocin and dopamine release → sacral parasympathetic outflow. Centrally mediated erection/arousal, not peripheral like PDE5 inhibitors. MT-II also activates nucleus accumbens via oxytocin in social contexts (PMID: 38253222).

MC3R/MC4R activation (appetite/energy): Hypothalamic melanocortin signaling reduces food intake and increases energy expenditure. MT-2 also acts in the central amygdala via AMPK pathway (PMID: 38604549). Can bypass 5-HT2CR dysfunction (PMID: 38815086).

MC4R in astrocytes (neuroprotection): Astrocytic MC4R activation suppresses MAPK and NF-kB signaling, protecting the blood-brain barrier in neuroinflammatory models (PMID: 41454349).

Mast cell / histamine pathway (non-MCR): MT-II-induced hypothermia is mast cell-dependent and mediated via histamine H1 receptors, INDEPENDENT of canonical melanocortin receptors MC1/3/4/5 (PMID: 29812984). This is a novel non-MCR pathway — abolished in Kit (mast cell-deficient) mice. Implications: some MT-2 side effects may not be addressable by MCR selectivity engineering.

Cardiovascular — CNS melanocortin and cardiac function: Long-term CNS melanocortin pathway activation (via MT-II) conferred remarkable cardiac protection post-MI in mice: improved substrate oxidation, cardiomyocyte contractility, Ca²⁺ coupling, and mitochondrial efficiency (PMID: 33532666). However, chronic MT-II infusion in WT mice also caused transient MAP +11 mmHg and HR +126 bpm, abolished in NPY-knockout mice (PMID: 29351428). Net cardiovascular effect is bidirectional and dose/duration-dependent.

Insulin sensitivity: Peripheral MT-II improved insulin sensitivity and glucose tolerance in OLETF rats beyond what pair-feeding achieved — suggesting direct metabolic effects independent of appetite suppression (PMID: 15350695, Nagoya University, Japan).

Peripheral nerve regeneration: MT-II promoted sciatic nerve regeneration (crush model) and protected against cisplatin-induced neuropathy at 20 ug/kg/48h with an inverted U-shaped dose response (2 and 50 ug were ineffective) (PMID: 12591111). This narrow therapeutic window is notable.

Social behavior — sex-dependent: Neonatal MT-II treatment showed clear sex-dependent effects in prairie voles: facilitated adult partner preference formation in females only; reduced play fighting in males only (PMID: 24923239, Barrett et al. 2014). Strongest direct evidence of sex-specific MT-II behavioral effects.

MC4R ventral striatum — odor aversion and yawning: MC4R signaling in olfactory tubercle vs nucleus accumbens differentially modulates odor aversion and yawning in mice (Alam et al. 2025, Kochi University, Japan). Relevant to MT-II side effect of yawning.

5-HT2C in erectile mechanism: 5-HT2C receptor activation mediates MT-II proerectile effects; the serotonin pathway is DOWNSTREAM of melanocortin in erectile function (PMID: 18582863, Astellas, Japan).

MC4R trafficking — GRP78 chaperone: GRP78 binds MC4R and regulates its cell surface trafficking; knockdown in PVN increased body weight on HFD (PMID: 30209265, Korea University, South Korea). Novel MC4R regulatory mechanism.

Pharmacokinetics (Limited Data)

• Half-life: ~2 hours (estimated from clinical observation)
• Route: Subcutaneous injection (also intranasal, but poorly characterized bioavailability)
• Onset of pigmentation: 5-7 days with daily dosing; full effect 3-6 weeks
• Onset of sexual effects: 1-4 hours post-injection
• Metabolism: Hepatic proteolysis (inferred; no formal ADME study published)
• Peak plasma, Tmax, distribution, protein binding: ALL UNKNOWN
• No formal ADME study has ever been published in humans
• Calcium is a critical cofactor for MC4R agonist binding and receptor function (PMID: 41834719)

Discovery History

1. 1980s: Hruby and Hadley at University of Arizona synthesize MT-2 as a superpotent analog of alpha-MSH for photoprotective tanning (PMID: 9760697)
2. 1996: Phase I trial demonstrates tanning efficacy but significant nausea (PMID: 8637402)
3. 1996-2000: Serendipitous discovery of pro-erectile effects during Phase I — leads to ED trials (PMID: 15996790)
4. 1998: Double-blind crossover confirms erectile effect in psychogenic ED (PMID: 9679884)
5. 2000: Studies in organic ED and sexual motivation (PMIDs: 11018622, 11035391)
6. ~2003: Pharmaceutical development of MT-2 abandoned due to non-selective side-effect profile
7. 2000s onward: PT-141/bremelanotide (MT-2 metabolite) developed as MC4R-preferring compound
8. 2009: BMJ raises alarm about unregulated use in general population (PMID: 19224885)
9. 2019: Bremelanotide approved as Vyleesi (PMID: 31599840); afamelanotide approved as Scenesse
10. 2010s-2020s: MT-2 proliferates on gray market globally; adverse event case reports accumulate
11. 2026: TGA reclassifies to Schedule 9; regulatory enforcement intensifies worldwide

Melanocortin Receptor System Overview

The melanocortin system comprises 5 G-protein-coupled receptors (MC1R-MC5R), the endogenous agonists (alpha-MSH, beta-MSH, gamma-MSH, ACTH), and the endogenous antagonists (agouti-related protein/AgRP and agouti signaling protein/ASIP). MT-2 mimics alpha-MSH but with much higher potency and longer half-life due to its cyclic structure and amino acid substitutions.

Key review: Hadley ME, Dorr RT (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. PMID: 16412534

Melanocortin system review: Sweeney P et al. (2023). Targeting the central melanocortin system for metabolic disorders. Nat Rev Endocrinol. PMID: 37365323

Recent Research (2022-2026)

Chemistry / Selectivity:

• Tomassi S et al. (2022) developed MT-2 analogs with 18-fold MC1R selectivity over MC4R using CLIPS technology (PMID: 35188390)
• Okano S et al. (2024) applied novel peptide stapling (tryptathionine/bis-indole) to MT-II achieving sub-nM MC1R affinity (PMID: 38285527)

Safety / Case Reports (new):

• Dickson D, Hlaing Htwe S (2025) — first case of pyoderma gangrenosum at MT-2 injection sites (PMID: 41487785)
• Resnick G et al. (2026) — PRISMA systematic review of 68 tanning agent studies; confirms MT-2 serious AEs (PMID: 41890775)
• Lai FY et al. (2025) — Irish dermatology clinic survey (N=104): documents MT-2 use patterns, addiction-like tanning behaviors (PMID: 40584950)

Mechanism / Preclinical:

• Inozemtseva LS et al. (2024) — MT-2 reversed chronic stress-induced anhedonia in rats, restored hippocampal BDNF (PMID: 39442746). Kurchatov Institute/Moscow State University.
• Castro G et al. (2024) — MT-II in central amygdala suppresses feeding via AMPK pathway, not just hypothalamus (PMID: 38604549)
• Liu H et al. (2024) — MT-II bypasses 5-HT2CR dysfunction for appetite suppression in mice (PMID: 38815086). Baylor / Central South University, China.
• Ford CL et al. (2024) — MT-II activates nucleus accumbens via oxytocin in social contexts; implications for autism/social deficits (PMID: 38253222). Emory University.
• Wang Y et al. (2025) — Astrocytic MC4R mediates BBB protection and anti-neuroinflammation in EAE/MS model (PMID: 41454349). Harbin Medical University, China.

Reviews:

• Jamaluddin A et al. (2026) — Ca²⁺ as cofactor for MC4R; Gs vs Gq differential effects on appetite vs cardiovascular function (PMID: 41834719). Birmingham/Cambridge.
• Prindle CR et al. (2026) — MC3R+MC4R dual modulation may be optimal for obesity; past MC4R clinical failures reviewed (PMID: 41907544). Endevica Bio.

Cardiovascular / Metabolic / Nerve:

• Gava FN et al. (2021) — Long-term CNS melanocortin activation conferred cardiac protection post-MI: improved contractility, substrate oxidation, mitochondrial efficiency (PMID: 33532666). JACC Basic Transl Sci.
• da Silva AA et al. (2018) — Chronic MT-II: transient MAP +11 mmHg, HR +126 bpm, abolished in NPY-KO mice. Chronic MC4R activation did NOT replicate leptin's antidiabetic effects (PMID: 29351428).
• Jain S et al. (2018) — MT-II hypothermia is mast cell-dependent via H1 receptors, independent of MCR1/3/4/5 (PMID: 29812984). NIH.
• Banno R et al. (2004) — Peripheral MT-II improved insulin sensitivity in OLETF rats (PMID: 15350695). Nagoya University, Japan.
• Ter Laak MP et al. (2003) — MT-II promoted sciatic nerve regeneration + cisplatin neuropathy protection; inverted U dose-response (PMID: 12591111).
• Wekwejt P et al. (2023) — MT-II reversed HF-diet-induced memory impairment in zebrafish (PMID: 37478579).
• McMillan TR et al. (2021) — MT-II partially rescued thermogenic impairment in PACAP-deficient mice (PMID: 33332767).
• Gavini CK et al. (2018) — Inherently lean rats: enhanced skeletal muscle response to central melanocortin stimulation (PMID: 29566460).

Sex-Specific / Social Behavior:

• Barrett CE et al. (2014) — Neonatal MT-II: sex-dependent effects in prairie voles (partner preference in females, reduced play fighting in males) (PMID: 24923239).
• Paiva L et al. (2017) — MT-II induced Fos expression in magnocellular oxytocin neurons; increased firing but NOT somatodendritic OT release (PMID: 28009464).

East Asian Research:

• Suzuki H et al. (2025) — ²¹¹At-labeled alpha-MSH analog for targeted alpha therapy of metastatic melanoma (PMID: 39828865). Chiba University / Osaka University, Japan.
• Kimura Y et al. (2008) — 5-HT2C receptor mediates MT-II proerectile effects; serotonin downstream of melanocortin (PMID: 18582863). Astellas, Japan.
• Yoon YR et al. (2018) — GRP78 binds MC4R, regulates trafficking; PVN knockdown increased body weight on HFD (PMID: 30209265). Korea University, South Korea.
• Alam MS et al. (2025) — MC4R in ventral striatum: differential odor aversion and yawning modulation. Kochi University, Japan.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

NCT07437560 details: Randomized, placebo-controlled (MT-II + NB-UVB vs Placebo + NB-UVB). Ages 18-65. Primary endpoint: VASI total score change at 24 weeks. Secondary: VASI50 response rate, time to first repigmentation, melanin index (colorimetry), DLQI, AE incidence. Excludes prior melanoma, dysplastic nevus syndrome, uncontrolled HTN/CVD. Sponsor: Hudson Biotech. First registered Phase 2 RCT of MT-II itself in decades.

No other MT-2-specific trials registered on ClinicalTrials.gov. No trials found in JPRN (Japan), CRiS (South Korea), or ChiCTR (China). Related compounds: bremelanotide has 10 registered trials (HSDD, obesity); afamelanotide has 23 (EPP, vitiligo, actinic keratoses).

Regulatory Status (as of April 2026)

• ChEMBL ID: CHEMBL430239
• BioMCP regulatory: Not found in FDA/EMA approved drug databases. No NDA/BLA on file.
• Regulatory trajectory (2026): Tightening globally, not liberalizing. TGA Schedule 9 is the most aggressive action to date. No jurisdiction is moving toward approval of MT-2.

Hair Darkening & Gray Hair Repigmentation (Emerging)

MT-2 activates MC1R in hair follicle melanocytes, not just epidermal melanocytes. This has implications for hair color:

Community evidence: Users consistently report darker hair during MT-2 use, most visible in those with red/light hair (eumelanin boost over baseline pheomelanin). Reversible upon cessation in most cases. Some long-term users report permanent baseline darkening.

Mechanism — what supports it:

• MC1R is expressed on hair follicle melanocytes and melanocyte stem cells (McSCs)
• MC1R signaling is required for McSC migration from the follicle niche (PMID: 23749232, Nature Medicine)
• Constitutive activation of MC1R-coupled Gαs pathway increases hair pigmentation in mice (PMID: 40356280, 2025)
• Palmitoyl tetrapeptide-20 (PTP20), a topical α-MSH agonist, upregulated MC1R in human hair follicles and showed hair repigmentation in 15 men with premature graying after 3 months (PMID: 30222197)
• Dersimelagon (MT-7117), an oral MC1R-selective agonist from Mitsubishi Tanabe Pharma (Japan), induced coat color darkening in mice at ≥0.3 mg/kg/day (PMID: 35665216). Phase 1 in humans showed melanin density increase at 150-300 mg/day (PMID: 37060458). Currently in Phase 2/3 for EPP/XLP.

Mechanism — what limits it:

• MC1R is dispensable for acute stress-induced graying (PMID: 33382172, Harvard). Stress-graying works via sympathetic norepinephrine depleting McSCs, not via melanocortin pathway. MC1R agonists may help age-related graying but likely NOT stress-related graying.
• Fully white hair (complete McSC depletion) cannot be repigmented by MC1R activation — no melanocytes remain to stimulate. Only partially gray (salt-and-pepper, residual melanocytes present) is theoretically responsive.
• No clinical study has ever measured MT-2's effect on hair pigmentation as a primary endpoint.

The selective alternative: Dersimelagon (MT-7117) from Japan is the most clinically advanced MC1R agonist for melanogenesis — oral, MC1R-selective, proper PK data, currently in Phase 2/3. If hair repigmentation is the goal, dersimelagon is the compound to watch, not MT-2.

Melanotan II vs Melanotan I (Afamelanotide/Scenesse)

Key insight: Afamelanotide's MC1R selectivity eliminated the sexual, appetite, and cardiovascular side effects of MT-2 while preserving the pigmentation/photoprotection benefit. Selectivity matters.

Product Quality Risk (MAJOR)

MT-2 is purchased almost exclusively from unregulated gray-market vendors. Analysis of confiscated products has found:

• Variable peptide content (0-120% of claimed amount)
• Bacterial endotoxin contamination
• Heavy metal contamination
• Incorrect peptides (wrong sequence)
• Degradation products

A 2018 analysis of falsified biotechnology drugs specifically flagged melanotan products as a major concern (PMID: 30165334). A 2018 review characterized the underground melanotan market (PMID: 30142729).

Ataraxia Verdict (as of 2026-04-14)

Hype Check

Overblown claims:

• "Safe tanning alternative" — Not safe. No long-term safety data. Case reports of melanoma, eruptive nevi, renal infarction, priapism, rhabdomyolysis. The "no UV needed" claim is technically true but misleadingly implies safety.
• "FDA-approved peptide" — FALSE. MT-2 has never been submitted to or approved by the FDA. Bremelanotide (PT-141/Vyleesi) is FDA-approved, but that is a different compound.
• "Weight loss peptide" — Appetite suppression is a side effect, not a validated indication. No weight loss trials exist.
• "Neuroprotective" — Animal data only. No human evidence.

Legitimately supported (with major caveats):

• Increases skin pigmentation — confirmed in Phase I (PMID: 8637402), but at a dose that caused severe nausea in most subjects
• Pro-erectile effects — confirmed in small RCT for psychogenic ED (PMID: 9679884), but the derivative bremelanotide is the approved, better-characterized option
• Melanocortin receptor agonism — well-characterized pharmacology, but non-selectivity is the core problem

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale below.

Evidence Gaps

• No pharmacokinetic data in humans — ADME entirely unknown
• No Phase III trials — development abandoned in early 2000s
• No long-term safety data — longest human exposure in trials was weeks
• No dose-finding study — community dosing protocols have zero clinical validation
• Melanoma risk unquantified — case reports exist, biological plausibility is strong, but no epidemiological study has measured the actual risk
• No systematic review or meta-analysis exists for MT-2 specifically
• Product quality is uncontrolled — all commercially available MT-2 is from unregulated sources
• Intranasal bioavailability unknown — nasal spray products may deliver highly variable doses
• Safety in women — all 4 clinical trials enrolled men only; zero female safety data
• No negative study problem — with only 4 small trials from the Arizona group, the publication landscape is extremely limited

Bias Flags (Mode 4: First Principles)

• Abandoned molecule bias: Pharmaceutical companies abandoned MT-2 not because it doesn't work, but because the non-selective profile made it unsuitable for FDA approval. The drug works — it's just too dirty pharmacologically.
• Gray-market amplification: MT-2's availability online has created a large user base whose anecdotal reports dominate the information landscape. Self-selected users who tolerate side effects are more likely to report positive experiences (survivorship bias).
• Derivative success bias: The approval of bremelanotide (Vyleesi) is sometimes cited to validate MT-2. This is a category error — bremelanotide has a different receptor profile, different formulation, and its own safety database. Aspirin being safe doesn't make salicylic acid safe to inject.
• Melanoma confounding: Melanoma case reports in MT-2 users are confounded by the fact that many MT-2 users also use UV tanning beds (which is itself a melanoma risk factor). Disentangling MT-2 risk from UV risk is impossible without controlled studies. However, the oral mucosal melanoma case (PMID: 40210573) is NOT UV-confounded — oral mucosa is not UV-exposed.
• Single research group: All 5 human trials came from the University of Arizona group. No independent replication of human data exists.
• "No melanoma epidemic" fallacy: Appeal to popularity. No surveillance system tracks MT-2 users. Melanoma latency is 10-20 years. Early mass adopters (~2009-2010) are just now entering the detection window.

First principles that survive scrutiny:

1. Stimulating melanocyte proliferation carries inherent oncological risk that scales with duration, regardless of the agent.
2. A compound abandoned by its own developers due to unacceptable side effects is not fit for unsupervised self-administration.
3. Product quality from unregulated sources is an independent risk that cannot be eliminated by dosing protocol.
4. Cosmetic tanning has zero medical benefit.
5. Approved selective derivatives exist for both MT-2 indications (afamelanotide for tanning/photoprotection, bremelanotide for sexual dysfunction).

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: UK vendors (TruTan, PrestigeTan, PureMT2) produce the "education" content that users consume — obvious conflict of interest. Near-zero negative content on social media (confirmed by BJD systematic review).
• Influencer economics: TikTok "Barbie drug" trend driven by beauty influencers (18-25 yo women, UK/Ireland). Derek/MPMD provides measured coverage. BBC investigation revealed the scale of promotional content.
• Counter-narrative manipulation: TGA's Schedule 9 reclassification and MHRA website closures represent genuine public health concern, not regulatory overreach. The oral mucosal melanoma case (non-UV-exposed tissue) weakens the "it's just the tanning beds" dismissal.
• Cui bono summary: Pro-MT-2: gray-market vendors (massive margins), tanning salons (MT-2 users still UV-tan), beauty influencers. Anti-MT-2: regulatory agencies (legitimate safety concern), dermatologists (diagnostic confusion from MT-2-induced nevi changes), competitors (Clinuvel/afamelanotide could benefit from MT-2 prohibition). The anti-MT-2 incentives are mostly legitimate safety concerns, not commercial suppression.
• Red team highlight (most concerning angle): Historical precedent. DES (synthetic hormone), thalidomide (abandoned drug used off-label) — both showed delayed harm decades later. MT-2 fits the pattern: abandoned pharmaceutical + mass underground adoption + delayed harm detection window. We may be in the "pre-discovery" phase of a public health problem.

10-angle red team summary:

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 1/10 — non-selective melanocortin agonist with purely cosmetic primary use (tanning), case reports of melanoma/dysplastic nevi and other serious adverse events, and approved alternatives exist for every legitimate indication (bremelanotide for sexual dysfunction, afamelanotide for photoprotection, sunless tanners for cosmetic tanning).
• Opportunity cost: Consuming entire risk budget on a cosmetic compound. Real cost includes mandatory dermatology monitoring (full skin exams every 3-6 months @ $200-400 each) on top of product cost.
• Verdict: SKIP
• Not CONDITIONAL — there is no condition under which MT-2 is the rational first choice when approved alternatives exist. For tanning: DHA spray tans or gradual sun exposure with sunscreen. For sexual dysfunction: bremelanotide (Vyleesi) with a physician. For photoprotection: afamelanotide (Scenesse) if medically indicated.

Bottom Line

Melanotan II works — it tans skin and causes erections, as confirmed in small but real human trials. But it was abandoned by its own developers 20+ years ago because the non-selective receptor profile creates an unacceptable side-effect profile. The melanoma risk is the elephant in the room: biologically plausible (MC1R stimulates the exact cells that become melanoma), supported by case reports including one non-UV-exposed oral mucosal melanoma, and epidemiologically unquantifiable because no one is tracking underground users. The TGA's Schedule 9 reclassification (Feb 2026) and MT-2's explicit exclusion from Kennedy HHS liberalization signal that regulators see this as genuinely dangerous. Two approved selective derivatives exist for both of MT-2's use cases. There is no rational clinical scenario where MT-2 is preferable to afamelanotide or bremelanotide, except that MT-2 is cheap and available without prescription — which is precisely what makes it dangerous.

Practical Notes

Reconstitution: Add bacteriostatic water slowly down vial side. Swirl gently, do not shake. Typical concentration: 10mg in 2mL BAC water = 500 mcg per 0.1 mL. Use within 30 days refrigerated.

Storage: Lyophilized: freezer (-20C) up to 2 years, or fridge (2-8C) 3-6 months. Reconstituted: fridge only, 30 days max. Protect from light.

Injection technique: Insulin syringe (29-31 gauge), subcutaneous at 45-90 degrees. Alcohol swab vial top each draw. Many users inject before bedtime to sleep through nausea. Rotate injection sites (abdomen, thigh, arm).

Nausea management (community practice, NOT validated): Start low (100-250 mcg), take antihistamine (diphenhydramine) 30 min before injection, inject before sleep. Some users report nausea tolerance develops over 1-2 weeks.

Cost: $20-80/vial (10mg) from gray-market vendors. Not insured. Not available from compounding pharmacies or by prescription in any country.

If someone insists on using: Start at lowest dose (100-250 mcg), inject before bed (nausea less noticeable during sleep), get a full dermatological skin exam with mole mapping before starting and every 3-6 months, absolutely avoid concurrent PDE5 inhibitors, monitor blood pressure, stop immediately for any new/changing moles.

What We Don't Know

• Long-term melanoma risk (biologically plausible, epidemiologically unquantified)
• Optimal dose for ANY human indication
• Human pharmacokinetics (ADME — absorption, distribution, metabolism, excretion)
• Whether eruptive nevi caused by MT-2 have increased malignant potential
• True cardiovascular risk profile beyond transient BP changes
• Product quality/purity of any commercially available MT-2 vial
• Whether lower community doses (250-500 mcg) are as effective as the Phase I dose (~1.75 mg)
• Interaction profile with any other medication (no formal studies)
• Whether tolerance develops to pigmentation or sexual effects with chronic use
• Safety in women (all clinical trials were in men)
• Intranasal bioavailability and dose equivalence to subcutaneous
• Effects on fertility or reproductive hormones with chronic use
• Whether melanocytic changes (new moles) are reversible after cessation
• Long-term cardiovascular effects
• Whether the antidepressant/antistress effect (animal data, PMID: 39442746) translates to humans
• Whether oral mucosal effects from injections (PMID: 41752902) indicate systemic melanocyte stimulation beyond skin
• Whether MC4R desensitization with chronic use explains the rare community reports of persistent libido loss
• Whether iris melanocyte stimulation causes eye color changes with chronic high-dose use (community reports, unverified)
• Whether mast cell activation via H1 receptors (PMID: 29812984) contributes to clinical side effects beyond hypothermia
• Net cardiovascular effect of chronic use: cardiac protection (PMID: 33532666) vs BP/HR elevation (PMID: 29351428) — bidirectional and unresolved
• Whether inverted U dose-response for nerve regeneration (PMID: 12591111) applies to other MT-2 effects
• Whether tanorexia/BDD in MT-2 users constitutes a clinically relevant behavioral dependency

References

Clinical Trials (All Human Data)

• Dorr RT, Lines R, Levine N et al. (1996). Phase I pilot: pigmentation efficacy + safety. Life Sci. PMID: 8637402
• Wessells H, Fuciarelli K, Hansen J et al. (1998). Double-blind crossover: psychogenic ED. J Urol. PMID: 9679884
• Wessells H, Gralnek D, Dorr R et al. (2000). Organic ED study. Urology. PMID: 11018622
• Wessells H, Levine N, Hadley ME et al. (2000). Sexual motivation study. Int J Impot Res. PMID: 11035391

Key Reviews

• Bohm M et al. (2025). Benefits and risks of chronic MC1R activation. J Eur Acad Dermatol Venereol. PMID: 39082868. MC1R activation may reduce melanoma via DNA repair but does NOT prevent melanoma.
• Hadley ME, Dorr RT (2006). Melanocortin peptide therapeutics: milestones and commercialization. Peptides. PMID: 16412534
• Hadley ME (2005). Discovery of melanocortin regulation of sexual function. Peptides. PMID: 15996790
• Uckert S et al. (2014). Melanocortin agonists in male/female sexual dysfunction. Expert Opin Investig Drugs. PMID: 25096243
• Hadley ME, Hruby VJ et al. (1998). Discovery of Melanotan-I and -II. Pharm Biotechnol. PMID: 9760697
• Sweeney P et al. (2023). Central melanocortin system for metabolic disorders. Nat Rev Endocrinol. PMID: 37365323
• Burian EA, Jemec GBE (2019). Eruptive melanocytic nevi review. Am J Clin Dermatol. PMID: 31119650
• Habbema L et al. (2017). Risks of unregulated use of alpha-MSH analogues. Int J Dermatol. PMID: 28266027. 4 melanoma case reports at time of publication.
• Weirath NA, Haskell-Luevano C (2024). Recommended Tool Compounds for MCR GPCRs. ACS Pharmacol Transl Sci. PMID: 39296259
• Gassas BM et al. (2014). MC4R as target for obesity treatment: systematic review. Peptides. PMID: 23774329
• Ngan V et al. (2021). Systemic photoprotection review (includes afamelanotide vs MT analogs). Photodermatol Photoimmunol Photomed. PMID: 33872410

Safety / Case Reports

• Nelson ME et al. (2012). Systemic toxicity + rhabdomyolysis. Clin Toxicol. PMID: 23121206
• Peters B et al. (2020). Renal infarction case + literature review. CEN Case Rep. PMID: 31953620
• Dreyer BA et al. (2019). Priapism. BMJ Case Rep. PMID: 30796078
• Mallory CW et al. (2021). Priapism. Sex Med. PMID: 33460908
• Hjuler KF, Lorentzen HF (2014). Melanoma associated with MT-2. Dermatology. PMID: 24355990
• Ong S, Bowling J (2012). Melanotan-associated melanoma in situ. Australas J Dermatol. PMID: 22724573
• Paurobally D et al. (2011). Melanotan-associated melanoma. Br J Dermatol. PMID: 21564053
• Alsabbagh A et al. (2025). Oral mucosal melanoma, nasal spray user. Int J Oral Maxillofac Surg. PMID: 40210573
• Bonchev A (2026). Oral mucosa pigmentation from MT-2 injections. Life (Basel). PMID: 41752902
• Dickson D, Hlaing Htwe S (2025). First case of pyoderma gangrenosum at melanotan injection sites. Cureus. PMID: 41487785
• Reid C et al. (2013). Atypical melanocytic naevi. Ir Med J. PMID: 23914578
• Schulze F et al. (2014). Eruptive nevi 24h after single injection. Eur J Dermatol. PMID: 24334249
• Cardones AR, Grichnik JM (2009). alpha-MSH-induced eruptive nevi. Arch Dermatol. PMID: 19380666
• Mang R et al. (2012). Dermoscopic nevi changes. Hautarzt. PMID: 23052015

Market / Regulatory / Quality / User Studies

• Resnick G et al. (2026). Tanning agents systematic review (PRISMA, 68 studies). Confirms MT-2 serious AEs. J Clin Aesthet Dermatol. PMID: 41890775
• Sidhu S et al. (2026). Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks. Int J Dermatol. PMID: 41559011
• Black TA et al. (2026). Sunless tanners review; flags melanotan safety/regulatory concerns. J Drugs Dermatol. PMID: 41493243
• Turnock LA, Hearne E (2024). Novel wellbeing and repair peptide use in the UK: Netnographic findings (493 threads, ~15,000 posts). Perf Enhance Health. DOI: 10.1016/j.peh.2024.100293
• Lai FY et al. (2025). Irish clinic survey (N=104): MT-2 use patterns, addiction-like tanning behavior. Skin Health Dis. PMID: 40584950
• Gilhooley E, Daly S, McKenna D (2021). Melanotan II User Experience: Qualitative Study of Online Forums. Dermatology. PMID: 34464955. 205 participants, 623 entries, UK/Ireland.
• Deville M, Charlier C (2024). "Barbie drug" forensic identification. J Forensic Sci. PMID: 39302005. Seized sample 30% purity.
• Evans-Brown M et al. (2009). Use of melanotan I and II in general population. BMJ. PMID: 19224885
• Adler NR et al. (2017). Unregulated MT-2 use — public health concern to Australian dermatologists. Australas J Dermatol. PMID: 28905366
• Callaghan DJ (2018). Underground melanotan market. Dermatol Online J. PMID: 30142729
• Janvier S et al. (2018). Falsification of biotechnology drugs. J Pharm Biomed Anal. PMID: 30165334

Bremelanotide (PT-141/Vyleesi) — MT-2 Derivative, FDA-Approved

• Kingsberg SA et al. (2019). RECONNECT Phase 3 trials for HSDD. Obstet Gynecol. PMID: 31599840
• Clayton AH et al. (2022). Safety profile across clinical development. J Womens Health. PMID: 35147466
• Althof S et al. (2019). Phase 2b dose-ranging. J Sex Med. PMID: 31277966
• White WB et al. (2017). Ambulatory BP monitoring with bremelanotide. J Hypertens. PMID: 27977473
• Clayton AH et al. (2016). Female sexual dysfunction dose-finding. Womens Health. PMID: 27181790

Afamelanotide (Melanotan I/Scenesse) — MC1R-Selective, FDA-Approved

• Polanska A et al. (2024). Afamelanotide in protoporphyria: a review. Postepy Dermatol Alergol. PMID: 38784937
• Minder EI et al. (2017). Pharmacokinetics and pharmacodynamics of afamelanotide. Clin Pharmacokinet. PMID: 28063031

Hair Pigmentation / MC1R in Hair Follicle

• Almeida Scalvino S et al. (2018). PTP20 (α-MSH agonist) for hair pigmentation. Int J Cosmet Sci. PMID: 30222197. 15 men with premature canities, topical, 3 months — upregulated MC1R in follicles.
• Zhang B et al. (2021). MC1R dispensable for stress-induced graying. Exp Dermatol. PMID: 33382172. Harvard — stress graying via sympathetic norepinephrine, not melanocortin.
• Chou WC et al. (2013). McSC migration to epidermis depends on MC1R signaling. Nat Med. PMID: 23749232
• Goff PS et al. (2025). Gαs-protein mutation increases hair pigmentation via MC1R pathway. Pigment Cell Melanoma Res. PMID: 40356280
• Suzuki T et al. (2022). Dersimelagon (MT-7117) melanogenic effect — coat darkening in mice. Skin Health Dis. PMID: 35665216. Mitsubishi Tanabe Pharma, Japan.
• Ogasawara A et al. (2023). Dersimelagon first-in-human Phase 1 — melanin density increase at 150-300 mg. Eur J Clin Pharmacol. PMID: 37060458. Mitsubishi Tanabe Pharma, Japan.
• Sato A et al. (2024). Discovery of dersimelagon — oral MC1R agonist. J Med Chem. PMID: 39641249. Mitsubishi Tanabe Pharma, Japan.

Receptor Pharmacology / Preclinical / Mechanism

• Inozemtseva LS et al. (2024). MT-2 antidepressant-like effects in chronic stress model. Eur J Pharmacol. PMID: 39442746. Kurchatov Institute/Moscow State University, Russia.
• Castro G et al. (2024). MT-II in central amygdala suppresses feeding via AMPK pathway. Mol Cell Endocrinol. PMID: 38604549
• Liu H et al. (2024). MT-II bypasses 5-HT2CR dysfunction for appetite suppression. Endocrinology. PMID: 38815086. Baylor/Central South University, China.
• Ford CL et al. (2024). MT-II activates nucleus accumbens via oxytocin in social contexts. Neuropharmacology. PMID: 38253222. Emory University.
• Wang Y et al. (2025). Astrocytic MC4R mediates BBB protection in MS model. J Neuroinflammation. PMID: 41454349. Harbin Medical University, China.
• Jamaluddin A et al. (2026). MC4R accessory proteins and cofactors review. J Neuroendocrinol. PMID: 41834719. Birmingham/Cambridge.
• Prindle CR et al. (2026). MC3R+MC4R dual modulation for obesity; past MC4R failures. Front Endocrinol. PMID: 41907544. Endevica Bio.
• Okano S et al. (2024). Novel peptide stapling applied to MT-II; sub-nM MC1R affinity. Chem Commun. PMID: 38285527
• Suzuki H et al. (2025). ²¹¹At-labeled alpha-MSH for targeted melanoma therapy. J Nucl Med. PMID: 39828865. Chiba/Osaka University, Japan.
• Tomassi S et al. (2022). CLIPSing MT-II: functionally selective hMCR agonists. J Med Chem. PMID: 35188390
• Wu JC et al. (2020). Topical MTII suppresses melanoma via PTEN/COX-2. Int J Mol Sci. PMID: 31968661
• Allard J, Giuliano F (2001). CNS agents in erectile dysfunction. Curr Urol Rep. PMID: 12084236

Cardiovascular / Metabolic / Nerve Regeneration

• Gava FN et al. (2021). Long-term CNS melanocortin activation confers cardiac protection post-MI. JACC Basic Transl Sci. PMID: 33532666
• da Silva AA et al. (2018). Chronic MT-II: transient MAP/HR increases, NPY-dependent. Am J Physiol Regul Integr Comp Physiol. PMID: 29351428
• Jain S et al. (2018). MT-II hypothermia via mast cells / histamine H1, independent of MCR. Am J Physiol Endocrinol Metab. PMID: 29812984. NIH.
• Banno R et al. (2004). Peripheral MT-II improved insulin sensitivity in OLETF rats. Peptides. PMID: 15350695. Nagoya University, Japan.
• Ter Laak MP et al. (2003). MT-II promoted nerve regeneration + cisplatin neuropathy protection; inverted U dose-response. Eur J Pharmacol. PMID: 12591111
• Wekwejt P et al. (2023). MT-II reversed HF-diet memory impairment in zebrafish. Biomed Pharmacother. PMID: 37478579
• McMillan TR et al. (2021). MT-II rescued PACAP-deficient thermogenic impairment. Exp Physiol. PMID: 33332767
• Gavini CK et al. (2018). Inherently lean rats: enhanced skeletal muscle response to central melanocortin. Obesity. PMID: 29566460

Sex-Specific / Social Behavior

• Barrett CE et al. (2014). Neonatal MT-II: sex-dependent partner preference + play fighting effects in prairie voles. Neuropharmacology. PMID: 24923239
• Paiva L et al. (2017). MT-II induced magnocellular oxytocin neuron Fos expression. J Neuroendocrinol. PMID: 28009464
• Kimura Y et al. (2008). 5-HT2C mediates MT-II proerectile effects. Eur J Pharmacol. PMID: 18582863. Astellas, Japan.
• Yoon YR et al. (2018). GRP78 binds MC4R, regulates trafficking. Exp Mol Med. PMID: 30209265. Korea University, South Korea.

Vitiligo / Comparator Studies

• Grimes PE et al. (2015). Afamelanotide + NB-UVB for vitiligo (RCT). JAMA Dermatol. PMID: 25230094. Key comparator for NCT07437560.
• Lim HW et al. (2020). Afamelanotide + NB-UVB for vitiligo in Asian patients. J Drugs Dermatol. PMID: 31987791